Trial Profile
A multicenter, open-labeled, dose-defining trial to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of tolvaptan in pediatric congestive heart failure (CHF) patients with volume overload
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 22 Jun 2022 Status changed from recruiting to completed.
- 21 Aug 2017 New trial record